eMedicine Specialties > Infectious Diseases > CNS Infections
Cysticercosis: Follow-up
Updated: Jul 25, 2008
Follow-up
Further Inpatient Care
- ICU monitoring is necessary in patients with uncontrolled seizures, elevated ICP, or severe extraparenchymal disease.
- If antiparasitic therapy is provided, patients should be hospitalized and monitored during the initial phase.
- As cysticerci die, neurologic symptoms may worsen because of an increased inflammatory response.
- Most symptoms associated with antiparasitic therapy develop within 3-5 days of beginning therapy.
- Antiparasitic therapy may then be completed in an outpatient setting.
- Prior initiation of therapy with antiparasitic medications or corticosteroids, the following steps should be taken:
- Apply a purified protein derivative (PPD) skin test. Patients in whom the PPD result is positive should be treated with isoniazid along with pyridoxine (vitamin B6) for the duration of their steroid treatment.
- Because many patients with cysticercosis also have risk factors for strongyloidiasis, these patients should be treated with ivermectin (200 μg/kg administered in two single doses two weeks apart before steroids are initiated.
- An ophthalmologist should perform an eye examination to exclude ocular cysticercosis.
Further Outpatient Care
- The initial brain reimaging should be performed two months after therapy completion.
- Parasite antigen levels typically fall by 3 months after successful treatment.
- For patient monitoring, the imaging should be performed on a biannual basis to monitor the cysts.
- If the cysts are growing in the absence of therapy, antiparasitic therapy should be considered.
- In patients with seizures due to neurocysticercosis without calcification, perform imaging studies every 3-6 months. If calcification develops, lifelong anticonvulsant therapy is indicated, and further imaging studies can be performed as needed.
- If results of imaging studies show normalization and seizures are under control after 2 years of therapy, anticonvulsants may be tapered, and further imaging can be performed as needed.
- Patients with calcified lesions and a seizure disorder should be maintained on anticonvulsants indefinitely, and they should undergo imaging studies only as needed.
- Monitor anticonvulsant serum levels to prevent toxicity.
Inpatient & Outpatient Medications
- Discharge medications may include steroids, anticonvulsants, antiparasitics, and cimetidine.
- The anticonvulsants carbamazepine and phenytoin are first-choice treatments.
- Antihelminthic agents: Antihelminthic medications are controversial. Reserve such treatment for select cases. When antihelminthics are used, albendazole is preferable to praziquantel.
Transfer
- Patients with extraparenchymal neurocysticercosis should be treated at hospitals with active neurosurgical and neurological services because emergency procedures such as shunt placement or ventriculostomy may be required in patients with worsening hydrocephalus.
- Arrange transfer if the facility is unable to provide neurologic or neurosurgical care.
Deterrence/Prevention
- Educate patients regarding routes of transmission of cysticerci ova.
- Meat inspection has been effective at preventing transmission of tapeworms in developed countries but has been uniformly unsuccessful in developing countries.
- In areas of endemic cysticercosis, avoid undercooked pork to reduce the risk of intestinal infection.
- Be vigilant about avoiding potential fecal-oral transmission to reduce the risk of neurocysticercosis while in endemic areas. Individuals traveling to such areas should observe the following guidelines:
- Eat only fruits and vegetables that you have peeled yourself.
- Thoroughly wash (with water from a clean source) all food prior to ingestion.
- Maintain good personal hygiene and wash hands prior to food preparation.
- Mass chemotherapy has been used to interrupt transmission in some areas of endemic infection, but disease usually returns within a few years.
- Mass anthelminthic therapy yields only limited success and may cause adverse neurologic events in individuals with undiagnosed neurocysticercosis who receive these drugs.
- Consider identifying human carriers of tapeworms, possibly based on a history of proglottid passage, and instituting targeted treatment.
- Serologic screening of the contacts of patients should also be considered in the management of cysticercosis, particularly in nonendemic countries when transmission may have occurred within a household (eg, via food prepared by a household worker from an endemic country).
- Vaccines for prevention of cysticercosis have proven effective for other Taenia species and are in development for T solium.
- Transmission of cysticercal infections to pigs can be prevented with the following measures:
- Changing pig-raising practices in endemic areas by confining the animals and preventing them from roaming freely to avoid contact with infectious ova excreted in human feces
- Improving sanitary conditions and proper disposal of human stool
- Possibly vaccinating pigs (Preliminary studies suggest this may be feasible.)
Complications
- Parenchymal disease causes seizures but few long-term complications. However, studies suggest that childhood infection may be associated with learning disabilities and cognitive dysfunction.
- Extraparenchymal disease may cause elevated ICP, resulting in herniation and death.
- Vasculitis associated with cisternal neurocysticercosis may cause strokes, communicating hydrocephalus, and death.
Prognosis
- Most patients with parenchymal cysticercosis either remain asymptomatic or develop a self-limited seizure disorder.
- Among patients who develop intracerebral calcifications, most have recurrent seizures unless treated with anticonvulsants. If treated with anticonvulsants, the seizures are generally easily controlled.
- Ventricular neurocysticercosis usually requires shunting.
- Neurosurgery may be complicated by focal neurologic damage.
- Shunt revisions are often needed unless patients are treated with corticosteroids or antiparasitic drugs. However, even with treatment, some still require subsequent revision.
- Prior to the use of corticosteroids and antiparasitic drugs, subarachnoid disease was associated with a 90% 10-year fatality rate, even with shunting. With current management, fatalities appear to be rare.
- Good evidence indicates that, once infected, patients are immune to reinfection.
Patient Education
- Patients and their family members should be educated on how to decrease the source of egg carriers by emphasizing improvement in sanitation, separation of pigs from humans, and food-preparation hygiene in endemic areas.
- Family members should be queried about symptoms suggestive of tapeworm infection, such as passing proglottids. They should be treated if symptoms are present.
- Family members should also be screened.
- Patients with seizures and their families should know proper seizure first-aid.
- Patients who have had seizures should know about possible driving restrictions, which, in the United States, vary from state to state.
- Patients who have received a VP shunt should be educated about the signs and symptoms of elevated ICP (possible shunt failure) and meningitis (secondary infection of indwelling hardware).
- For excellent patient education resources, please see eMedicine's Infections Center and Parasites and Worms Center.
Miscellaneous
Medicolegal Pitfalls
- Failure to consider the diagnosis and to perform appropriate testing (primarily neuroimaging studies)
- The symptoms of neurocysticercosis are nonspecific, but imaging studies usually confirm the diagnosis.
- The key to diagnosis is careful evaluation of patients who are at risk.
- Diagnostic testing in patients with seizures who have not undergone previous studies should include neuroimaging studies (either CT scanning or MRI).
- If patients have suggestive lesions, obtaining further history of exposure, serologic analyses, or imaging studies that show soft-tissue calcifications can confirm the diagnosis.
- Failure to promptly initiate therapy for elevated ICP
- As with other conditions, symptomatic increased ICP in neurocysticercosis is an emergency.
- Patients usually present with headaches, but the headaches may not be significantly different from those due to a wide range of other causes.
- Patients with headaches who also have symptoms of increased ICP or mass lesion require more emergent evaluation. These symptoms include nausea and vomiting, dizziness, visual changes, or abnormal neurologic examination findings.
- Obstructive hydrocephalus often requires surgical intervention.
Special Concerns
- Identification of the source of infection and prevention of further exposure is paramount in the care of neurocysticercosis.
- Cases of cysticercosis do not need to be reported to the CDC unless local transmission is suspected. In this case, the Division of Parasitic Diseases at the CDC can be contacted through state and local health departments. More information is available at the CDC Web site.
- In 1997, a study by Del Brutto et al found an association between neurocysticercosis and cerebral gliomas in adults, possibly due to astrocytic gliosis that surrounds the cyst. Further study and evaluation are needed.12
The authors and editors would like to acknowledge Dr. Martin Montes, Dr. Clinton White Jr., and Dr. Thomas P. Giordano, who were the original authors of this article. They would also like to acknowledge the prior contributions of Dr. John W King to the development and writing of this article.
More on Cysticercosis |
| Overview: Cysticercosis |
| Differential Diagnoses & Workup: Cysticercosis |
| Treatment & Medication: Cysticercosis |
Follow-up: Cysticercosis |
| References |
| Further Reading |
| « Previous Page |
References
Sorvillo FJ, DeGiorgio C, Waterman SH. Deaths from cysticercosis, United States. Emerg Infect Dis. Feb 2007;13(2):230-5. [Medline].
de Bittencourt PR, Adamolekum B, Bharucha N, et al. Epilepsy in the tropics: I. Epidemiology, socioeconomic risk factors, and etiology. Epilepsia. Nov 1996;37(11):1121-7. [Medline].
Wallin MT, Kurtzke JF. Neurocysticercosis in the United States: review of an important emerging infection. Neurology. Nov 9 2004;63(9):1559-64. [Medline].
Ong S, Talan DA, Moran GJ, et al. Neurocysticercosis in radiographically imaged seizure patients in U.S. emergency departments. Emerg Infect Dis. Jun 2002;8(6):608-13. [Medline].
Bern C, Garcia HH, Evans C, et al. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis. Nov 1999;29(5):1203-9. [Medline].
Del Brutto OH, Rajshekhar V, White AC Jr, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology. Jul 24 2001;57(2):177-83. [Medline].
Fleury A, Hernandez M, Fragoso G, et al. Detection of secreted cysticercal antigen: a useful tool in the diagnosis of inflammatory neurocysticercosis. Trans R Soc Trop Med Hyg. Sep-Oct 2003;97(5):542-6. [Medline].
White AC Jr, Robinson P, Kuhn R. Taenia solium cysticercosis: host-parasite interactions and the immune response. Chem Immunol. 1997;66:209-30. [Medline].
Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. Jan 15 2004;350(3):249-58. [Medline].
Kelley R, Duong DH, Locke GE. Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. Neurosurgery. Apr 2002;50(4):757-61; discussion 761-2. [Medline].
Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. Jan 15 2004;350(3):249-58. [Medline].
Del Brutto OH, Castillo PR, Mena IX, et al. Neurocysticercosis among patients with cerebral gliomas. Arch Neurol. Sep 1997;54(9):1125-8. [Medline].
Del Brutto OH. Neurocysticercosis. Semin Neurol. Sep 2005;25(3):243-51. [Medline].
Del Brutto OH, Santibanez R, Noboa CA, et al. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology. Feb 1992;42(2):389-92. [Medline].
Garcia HH, Gilman RH, Tovar MA, et al. Factors associated with Taenia solium cysticercosis: analysis of nine hundred forty-six Peruvian neurologic patients. Cysticercosis Working Group in Peru (CWG). Am J Trop Med Hyg. Feb 1995;52(2):145-8. [Medline].
García HH, Del Brutto OH. Imaging findings in neurocysticercosis. Acta Trop. Jun 2003;87(1):71-8. [Medline].
García HH, Evans CA, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. Oct 2002;15(4):747-56. [Medline].
Gordon E, Cartwright M, Avasarala J. Ventricular obstruction from neurocysticercosis. Arch Neurol. Jun 2005;62(6):1018. [Medline].
Gravori T, Steineke T, Bergsneider M. Endoscopic removal of cisternal neurocysticercal cysts. Technical note. Neurosurg Focus. Jun 15 2002;12(6):e7. [Medline].
Immunetics, Inc. Qualicode Cysticecosis Western Blot Kit. Immunetics [serial online]. 1997;Available at Immunetics-Qualicode Cysticecosis Western Blot Test Kit.
Kraft R. Cysticercosis: an emerging parasitic disease. Am Fam Physician. Jul 1 2007;76(1):91-6. [Medline].
Nainiwal S, Chand M, Verma L, et al. Intraocular live cysticercus larva. Ophthalmic Surg Lasers Imaging. Nov-Dec 2003;34(6):464-6. [Medline].
Salinas R, Counsell C, Prasad K, et al. Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. Trop Med Int Health. Nov 1999;4(11):713-8. [Medline].
Sharma T, Sinha S, Shah N, et al. Intraocular cysticercosis: clinical characteristics and visual outcome after vitreoretinal surgery. Ophthalmology. May 2003;110(5):996-1004. [Medline].
Sotelo J, Escobedo F, Penagos P. Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial. Arch Neurol. May 1988;45(5):532-4. [Medline].
Sundaram PM, Jayakumar N, Noronha V. Extraocular muscle cysticercosis - a clinical challenge to the ophthalmologists. Orbit. Dec 2004;23(4):255-62. [Medline].
White AC Jr. Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis. Feb 1997;24(2):101-13; quiz 114-5. [Medline].
White AC Jr, Robinson P, Kuhn R. Taenia solium cysticercosis: host-parasite interactions and the immune response. Chem Immunol. 1997;66:209-30. [Medline].
Keywords
cysticercosis, tapeworm infection, tapeworms, Taenia solium, T solium, pork tapeworm, tapeworm, neurocysticercosis, extraneural cysticercosis, parenchymal neurocysticercosis, extraparenchymal neurocysticercosis, NCC, intestinal tapeworm, intestinal tapeworm infection, cysticercal encephalitis, cysticercal meningoencephalitis, tapeworm encephalitis, parasitosis, subarachnoid neurocysticercosis, ocular cysticercosis, subcutaneous cysticercosis, intramuscular cysticercosis
Follow-up: Cysticercosis